Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis
Purpose Small cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment. Methods We retrospectively assessed data of 120 SCLC patients who failed first-line treatmen...
Ausführliche Beschreibung
Autor*in: |
Korkmaz, T. [verfasserIn] Seber, S. [verfasserIn] Kefeli, U. [verfasserIn] Sari, E. [verfasserIn] Canhoroz, M. [verfasserIn] Oven, B. [verfasserIn] Yildirim, E. [verfasserIn] Yasar, N. [verfasserIn] Aydin, D. [verfasserIn] Balvan, O. [verfasserIn] Sener, N. [verfasserIn] Yuksel, S. [verfasserIn] Mert, A. [verfasserIn] Polat, O. [verfasserIn] Yumuk, F. [verfasserIn] Kanat, O. [verfasserIn] Gumus, M. [verfasserIn] Turhal, N. S. [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2012 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
Enthalten in: Revista de oncología - Barcelona : Doyma, 2000, 15(2012), 7 vom: 10. Nov., Seite 535-540 |
---|---|
Übergeordnetes Werk: |
volume:15 ; year:2012 ; number:7 ; day:10 ; month:11 ; pages:535-540 |
Links: |
---|
DOI / URN: |
10.1007/s12094-012-0960-6 |
---|
Katalog-ID: |
SPR02426041X |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR02426041X | ||
003 | DE-627 | ||
005 | 20230519164619.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201006s2012 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s12094-012-0960-6 |2 doi | |
035 | |a (DE-627)SPR02426041X | ||
035 | |a (SPR)s12094-012-0960-6-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q ASE |
100 | 1 | |a Korkmaz, T. |e verfasserin |4 aut | |
245 | 1 | 0 | |a Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis |
264 | 1 | |c 2012 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Purpose Small cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment. Methods We retrospectively assessed data of 120 SCLC patients who failed first-line treatment and received second-line treatment at three medical oncology centers. Results Median age of group was 58. 82 % had an ECOG PS of 0–1 at the time of relapse. 39 % were at limited stage (LS) at the time of diagnosis. Patients who progressed more than 3 months after first-line therapy were categorized as having platinum-sensitive disease (PSD) (64 %). The number of patients who received platin-based combination treatment was 33 (27 %). The median OS time starting from the initiation of second-line treatment was 7 months. Multivariate analysis identified PS (p = 0.006), extent of disease at diagnosis (0.014) and PSD (0.001) as the independent prognostic factors for survival. Subgroup analyses of the patients with PSD indicated platin rechallenge yields higher progression-free survival, overall survival and overall response rate. Conclusion Patients with good ECOG PS,who have PSD or initially presenting with LS, have a good prognosis and in patients with PSD, platinum-based therapy would be more appropriate. | ||
650 | 4 | |a Platinum sensitive disease |7 (dpeaa)DE-He213 | |
650 | 4 | |a Platinum refracter disease |7 (dpeaa)DE-He213 | |
650 | 4 | |a Second-line chemotherapy |7 (dpeaa)DE-He213 | |
650 | 4 | |a Small cell lung cancer |7 (dpeaa)DE-He213 | |
700 | 1 | |a Seber, S. |e verfasserin |4 aut | |
700 | 1 | |a Kefeli, U. |e verfasserin |4 aut | |
700 | 1 | |a Sari, E. |e verfasserin |4 aut | |
700 | 1 | |a Canhoroz, M. |e verfasserin |4 aut | |
700 | 1 | |a Oven, B. |e verfasserin |4 aut | |
700 | 1 | |a Yildirim, E. |e verfasserin |4 aut | |
700 | 1 | |a Yasar, N. |e verfasserin |4 aut | |
700 | 1 | |a Aydin, D. |e verfasserin |4 aut | |
700 | 1 | |a Balvan, O. |e verfasserin |4 aut | |
700 | 1 | |a Sener, N. |e verfasserin |4 aut | |
700 | 1 | |a Yuksel, S. |e verfasserin |4 aut | |
700 | 1 | |a Mert, A. |e verfasserin |4 aut | |
700 | 1 | |a Polat, O. |e verfasserin |4 aut | |
700 | 1 | |a Yumuk, F. |e verfasserin |4 aut | |
700 | 1 | |a Kanat, O. |e verfasserin |4 aut | |
700 | 1 | |a Gumus, M. |e verfasserin |4 aut | |
700 | 1 | |a Turhal, N. S. |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Revista de oncología |d Barcelona : Doyma, 2000 |g 15(2012), 7 vom: 10. Nov., Seite 535-540 |w (DE-627)385985452 |w (DE-600)2143451-7 |x 1578-195X |7 nnns |
773 | 1 | 8 | |g volume:15 |g year:2012 |g number:7 |g day:10 |g month:11 |g pages:535-540 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12094-012-0960-6 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_70 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_90 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_100 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_120 | ||
912 | |a GBV_ILN_152 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_171 | ||
912 | |a GBV_ILN_187 | ||
912 | |a GBV_ILN_224 | ||
912 | |a GBV_ILN_250 | ||
912 | |a GBV_ILN_281 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_370 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_702 | ||
951 | |a AR | ||
952 | |d 15 |j 2012 |e 7 |b 10 |c 11 |h 535-540 |
author_variant |
t k tk s s ss u k uk e s es m c mc b o bo e y ey n y ny d a da o b ob n s ns s y sy a m am o p op f y fy o k ok m g mg n s t ns nst |
---|---|
matchkey_str |
article:1578195X:2012----::oprsnfeodieramnotoebtenestvadercoymlcllncne |
hierarchy_sort_str |
2012 |
publishDate |
2012 |
allfields |
10.1007/s12094-012-0960-6 doi (DE-627)SPR02426041X (SPR)s12094-012-0960-6-e DE-627 ger DE-627 rakwb eng 610 ASE Korkmaz, T. verfasserin aut Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose Small cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment. Methods We retrospectively assessed data of 120 SCLC patients who failed first-line treatment and received second-line treatment at three medical oncology centers. Results Median age of group was 58. 82 % had an ECOG PS of 0–1 at the time of relapse. 39 % were at limited stage (LS) at the time of diagnosis. Patients who progressed more than 3 months after first-line therapy were categorized as having platinum-sensitive disease (PSD) (64 %). The number of patients who received platin-based combination treatment was 33 (27 %). The median OS time starting from the initiation of second-line treatment was 7 months. Multivariate analysis identified PS (p = 0.006), extent of disease at diagnosis (0.014) and PSD (0.001) as the independent prognostic factors for survival. Subgroup analyses of the patients with PSD indicated platin rechallenge yields higher progression-free survival, overall survival and overall response rate. Conclusion Patients with good ECOG PS,who have PSD or initially presenting with LS, have a good prognosis and in patients with PSD, platinum-based therapy would be more appropriate. Platinum sensitive disease (dpeaa)DE-He213 Platinum refracter disease (dpeaa)DE-He213 Second-line chemotherapy (dpeaa)DE-He213 Small cell lung cancer (dpeaa)DE-He213 Seber, S. verfasserin aut Kefeli, U. verfasserin aut Sari, E. verfasserin aut Canhoroz, M. verfasserin aut Oven, B. verfasserin aut Yildirim, E. verfasserin aut Yasar, N. verfasserin aut Aydin, D. verfasserin aut Balvan, O. verfasserin aut Sener, N. verfasserin aut Yuksel, S. verfasserin aut Mert, A. verfasserin aut Polat, O. verfasserin aut Yumuk, F. verfasserin aut Kanat, O. verfasserin aut Gumus, M. verfasserin aut Turhal, N. S. verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 15(2012), 7 vom: 10. Nov., Seite 535-540 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:15 year:2012 number:7 day:10 month:11 pages:535-540 https://dx.doi.org/10.1007/s12094-012-0960-6 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 15 2012 7 10 11 535-540 |
spelling |
10.1007/s12094-012-0960-6 doi (DE-627)SPR02426041X (SPR)s12094-012-0960-6-e DE-627 ger DE-627 rakwb eng 610 ASE Korkmaz, T. verfasserin aut Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose Small cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment. Methods We retrospectively assessed data of 120 SCLC patients who failed first-line treatment and received second-line treatment at three medical oncology centers. Results Median age of group was 58. 82 % had an ECOG PS of 0–1 at the time of relapse. 39 % were at limited stage (LS) at the time of diagnosis. Patients who progressed more than 3 months after first-line therapy were categorized as having platinum-sensitive disease (PSD) (64 %). The number of patients who received platin-based combination treatment was 33 (27 %). The median OS time starting from the initiation of second-line treatment was 7 months. Multivariate analysis identified PS (p = 0.006), extent of disease at diagnosis (0.014) and PSD (0.001) as the independent prognostic factors for survival. Subgroup analyses of the patients with PSD indicated platin rechallenge yields higher progression-free survival, overall survival and overall response rate. Conclusion Patients with good ECOG PS,who have PSD or initially presenting with LS, have a good prognosis and in patients with PSD, platinum-based therapy would be more appropriate. Platinum sensitive disease (dpeaa)DE-He213 Platinum refracter disease (dpeaa)DE-He213 Second-line chemotherapy (dpeaa)DE-He213 Small cell lung cancer (dpeaa)DE-He213 Seber, S. verfasserin aut Kefeli, U. verfasserin aut Sari, E. verfasserin aut Canhoroz, M. verfasserin aut Oven, B. verfasserin aut Yildirim, E. verfasserin aut Yasar, N. verfasserin aut Aydin, D. verfasserin aut Balvan, O. verfasserin aut Sener, N. verfasserin aut Yuksel, S. verfasserin aut Mert, A. verfasserin aut Polat, O. verfasserin aut Yumuk, F. verfasserin aut Kanat, O. verfasserin aut Gumus, M. verfasserin aut Turhal, N. S. verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 15(2012), 7 vom: 10. Nov., Seite 535-540 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:15 year:2012 number:7 day:10 month:11 pages:535-540 https://dx.doi.org/10.1007/s12094-012-0960-6 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 15 2012 7 10 11 535-540 |
allfields_unstemmed |
10.1007/s12094-012-0960-6 doi (DE-627)SPR02426041X (SPR)s12094-012-0960-6-e DE-627 ger DE-627 rakwb eng 610 ASE Korkmaz, T. verfasserin aut Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose Small cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment. Methods We retrospectively assessed data of 120 SCLC patients who failed first-line treatment and received second-line treatment at three medical oncology centers. Results Median age of group was 58. 82 % had an ECOG PS of 0–1 at the time of relapse. 39 % were at limited stage (LS) at the time of diagnosis. Patients who progressed more than 3 months after first-line therapy were categorized as having platinum-sensitive disease (PSD) (64 %). The number of patients who received platin-based combination treatment was 33 (27 %). The median OS time starting from the initiation of second-line treatment was 7 months. Multivariate analysis identified PS (p = 0.006), extent of disease at diagnosis (0.014) and PSD (0.001) as the independent prognostic factors for survival. Subgroup analyses of the patients with PSD indicated platin rechallenge yields higher progression-free survival, overall survival and overall response rate. Conclusion Patients with good ECOG PS,who have PSD or initially presenting with LS, have a good prognosis and in patients with PSD, platinum-based therapy would be more appropriate. Platinum sensitive disease (dpeaa)DE-He213 Platinum refracter disease (dpeaa)DE-He213 Second-line chemotherapy (dpeaa)DE-He213 Small cell lung cancer (dpeaa)DE-He213 Seber, S. verfasserin aut Kefeli, U. verfasserin aut Sari, E. verfasserin aut Canhoroz, M. verfasserin aut Oven, B. verfasserin aut Yildirim, E. verfasserin aut Yasar, N. verfasserin aut Aydin, D. verfasserin aut Balvan, O. verfasserin aut Sener, N. verfasserin aut Yuksel, S. verfasserin aut Mert, A. verfasserin aut Polat, O. verfasserin aut Yumuk, F. verfasserin aut Kanat, O. verfasserin aut Gumus, M. verfasserin aut Turhal, N. S. verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 15(2012), 7 vom: 10. Nov., Seite 535-540 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:15 year:2012 number:7 day:10 month:11 pages:535-540 https://dx.doi.org/10.1007/s12094-012-0960-6 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 15 2012 7 10 11 535-540 |
allfieldsGer |
10.1007/s12094-012-0960-6 doi (DE-627)SPR02426041X (SPR)s12094-012-0960-6-e DE-627 ger DE-627 rakwb eng 610 ASE Korkmaz, T. verfasserin aut Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose Small cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment. Methods We retrospectively assessed data of 120 SCLC patients who failed first-line treatment and received second-line treatment at three medical oncology centers. Results Median age of group was 58. 82 % had an ECOG PS of 0–1 at the time of relapse. 39 % were at limited stage (LS) at the time of diagnosis. Patients who progressed more than 3 months after first-line therapy were categorized as having platinum-sensitive disease (PSD) (64 %). The number of patients who received platin-based combination treatment was 33 (27 %). The median OS time starting from the initiation of second-line treatment was 7 months. Multivariate analysis identified PS (p = 0.006), extent of disease at diagnosis (0.014) and PSD (0.001) as the independent prognostic factors for survival. Subgroup analyses of the patients with PSD indicated platin rechallenge yields higher progression-free survival, overall survival and overall response rate. Conclusion Patients with good ECOG PS,who have PSD or initially presenting with LS, have a good prognosis and in patients with PSD, platinum-based therapy would be more appropriate. Platinum sensitive disease (dpeaa)DE-He213 Platinum refracter disease (dpeaa)DE-He213 Second-line chemotherapy (dpeaa)DE-He213 Small cell lung cancer (dpeaa)DE-He213 Seber, S. verfasserin aut Kefeli, U. verfasserin aut Sari, E. verfasserin aut Canhoroz, M. verfasserin aut Oven, B. verfasserin aut Yildirim, E. verfasserin aut Yasar, N. verfasserin aut Aydin, D. verfasserin aut Balvan, O. verfasserin aut Sener, N. verfasserin aut Yuksel, S. verfasserin aut Mert, A. verfasserin aut Polat, O. verfasserin aut Yumuk, F. verfasserin aut Kanat, O. verfasserin aut Gumus, M. verfasserin aut Turhal, N. S. verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 15(2012), 7 vom: 10. Nov., Seite 535-540 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:15 year:2012 number:7 day:10 month:11 pages:535-540 https://dx.doi.org/10.1007/s12094-012-0960-6 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 15 2012 7 10 11 535-540 |
allfieldsSound |
10.1007/s12094-012-0960-6 doi (DE-627)SPR02426041X (SPR)s12094-012-0960-6-e DE-627 ger DE-627 rakwb eng 610 ASE Korkmaz, T. verfasserin aut Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose Small cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment. Methods We retrospectively assessed data of 120 SCLC patients who failed first-line treatment and received second-line treatment at three medical oncology centers. Results Median age of group was 58. 82 % had an ECOG PS of 0–1 at the time of relapse. 39 % were at limited stage (LS) at the time of diagnosis. Patients who progressed more than 3 months after first-line therapy were categorized as having platinum-sensitive disease (PSD) (64 %). The number of patients who received platin-based combination treatment was 33 (27 %). The median OS time starting from the initiation of second-line treatment was 7 months. Multivariate analysis identified PS (p = 0.006), extent of disease at diagnosis (0.014) and PSD (0.001) as the independent prognostic factors for survival. Subgroup analyses of the patients with PSD indicated platin rechallenge yields higher progression-free survival, overall survival and overall response rate. Conclusion Patients with good ECOG PS,who have PSD or initially presenting with LS, have a good prognosis and in patients with PSD, platinum-based therapy would be more appropriate. Platinum sensitive disease (dpeaa)DE-He213 Platinum refracter disease (dpeaa)DE-He213 Second-line chemotherapy (dpeaa)DE-He213 Small cell lung cancer (dpeaa)DE-He213 Seber, S. verfasserin aut Kefeli, U. verfasserin aut Sari, E. verfasserin aut Canhoroz, M. verfasserin aut Oven, B. verfasserin aut Yildirim, E. verfasserin aut Yasar, N. verfasserin aut Aydin, D. verfasserin aut Balvan, O. verfasserin aut Sener, N. verfasserin aut Yuksel, S. verfasserin aut Mert, A. verfasserin aut Polat, O. verfasserin aut Yumuk, F. verfasserin aut Kanat, O. verfasserin aut Gumus, M. verfasserin aut Turhal, N. S. verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 15(2012), 7 vom: 10. Nov., Seite 535-540 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:15 year:2012 number:7 day:10 month:11 pages:535-540 https://dx.doi.org/10.1007/s12094-012-0960-6 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 15 2012 7 10 11 535-540 |
language |
English |
source |
Enthalten in Revista de oncología 15(2012), 7 vom: 10. Nov., Seite 535-540 volume:15 year:2012 number:7 day:10 month:11 pages:535-540 |
sourceStr |
Enthalten in Revista de oncología 15(2012), 7 vom: 10. Nov., Seite 535-540 volume:15 year:2012 number:7 day:10 month:11 pages:535-540 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Platinum sensitive disease Platinum refracter disease Second-line chemotherapy Small cell lung cancer |
dewey-raw |
610 |
isfreeaccess_bool |
false |
container_title |
Revista de oncología |
authorswithroles_txt_mv |
Korkmaz, T. @@aut@@ Seber, S. @@aut@@ Kefeli, U. @@aut@@ Sari, E. @@aut@@ Canhoroz, M. @@aut@@ Oven, B. @@aut@@ Yildirim, E. @@aut@@ Yasar, N. @@aut@@ Aydin, D. @@aut@@ Balvan, O. @@aut@@ Sener, N. @@aut@@ Yuksel, S. @@aut@@ Mert, A. @@aut@@ Polat, O. @@aut@@ Yumuk, F. @@aut@@ Kanat, O. @@aut@@ Gumus, M. @@aut@@ Turhal, N. S. @@aut@@ |
publishDateDaySort_date |
2012-11-10T00:00:00Z |
hierarchy_top_id |
385985452 |
dewey-sort |
3610 |
id |
SPR02426041X |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR02426041X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519164619.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201006s2012 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s12094-012-0960-6</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR02426041X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12094-012-0960-6-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Korkmaz, T.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2012</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose Small cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment. Methods We retrospectively assessed data of 120 SCLC patients who failed first-line treatment and received second-line treatment at three medical oncology centers. Results Median age of group was 58. 82 % had an ECOG PS of 0–1 at the time of relapse. 39 % were at limited stage (LS) at the time of diagnosis. Patients who progressed more than 3 months after first-line therapy were categorized as having platinum-sensitive disease (PSD) (64 %). The number of patients who received platin-based combination treatment was 33 (27 %). The median OS time starting from the initiation of second-line treatment was 7 months. Multivariate analysis identified PS (p = 0.006), extent of disease at diagnosis (0.014) and PSD (0.001) as the independent prognostic factors for survival. Subgroup analyses of the patients with PSD indicated platin rechallenge yields higher progression-free survival, overall survival and overall response rate. Conclusion Patients with good ECOG PS,who have PSD or initially presenting with LS, have a good prognosis and in patients with PSD, platinum-based therapy would be more appropriate.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Platinum sensitive disease</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Platinum refracter disease</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Second-line chemotherapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Small cell lung cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Seber, S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kefeli, U.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sari, E.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Canhoroz, M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Oven, B.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yildirim, E.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yasar, N.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Aydin, D.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Balvan, O.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sener, N.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yuksel, S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mert, A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Polat, O.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yumuk, F.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kanat, O.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gumus, M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Turhal, N. S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Revista de oncología</subfield><subfield code="d">Barcelona : Doyma, 2000</subfield><subfield code="g">15(2012), 7 vom: 10. Nov., Seite 535-540</subfield><subfield code="w">(DE-627)385985452</subfield><subfield code="w">(DE-600)2143451-7</subfield><subfield code="x">1578-195X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:2012</subfield><subfield code="g">number:7</subfield><subfield code="g">day:10</subfield><subfield code="g">month:11</subfield><subfield code="g">pages:535-540</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s12094-012-0960-6</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">2012</subfield><subfield code="e">7</subfield><subfield code="b">10</subfield><subfield code="c">11</subfield><subfield code="h">535-540</subfield></datafield></record></collection>
|
author |
Korkmaz, T. |
spellingShingle |
Korkmaz, T. ddc 610 misc Platinum sensitive disease misc Platinum refracter disease misc Second-line chemotherapy misc Small cell lung cancer Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis |
authorStr |
Korkmaz, T. |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)385985452 |
format |
electronic Article |
dewey-ones |
610 - Medicine & health |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut |
collection |
springer |
remote_str |
true |
illustrated |
Not Illustrated |
issn |
1578-195X |
topic_title |
610 ASE Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis Platinum sensitive disease (dpeaa)DE-He213 Platinum refracter disease (dpeaa)DE-He213 Second-line chemotherapy (dpeaa)DE-He213 Small cell lung cancer (dpeaa)DE-He213 |
topic |
ddc 610 misc Platinum sensitive disease misc Platinum refracter disease misc Second-line chemotherapy misc Small cell lung cancer |
topic_unstemmed |
ddc 610 misc Platinum sensitive disease misc Platinum refracter disease misc Second-line chemotherapy misc Small cell lung cancer |
topic_browse |
ddc 610 misc Platinum sensitive disease misc Platinum refracter disease misc Second-line chemotherapy misc Small cell lung cancer |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Revista de oncología |
hierarchy_parent_id |
385985452 |
dewey-tens |
610 - Medicine & health |
hierarchy_top_title |
Revista de oncología |
isfreeaccess_txt |
false |
familylinks_str_mv |
(DE-627)385985452 (DE-600)2143451-7 |
title |
Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis |
ctrlnum |
(DE-627)SPR02426041X (SPR)s12094-012-0960-6-e |
title_full |
Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis |
author_sort |
Korkmaz, T. |
journal |
Revista de oncología |
journalStr |
Revista de oncología |
lang_code |
eng |
isOA_bool |
false |
dewey-hundreds |
600 - Technology |
recordtype |
marc |
publishDateSort |
2012 |
contenttype_str_mv |
txt |
container_start_page |
535 |
author_browse |
Korkmaz, T. Seber, S. Kefeli, U. Sari, E. Canhoroz, M. Oven, B. Yildirim, E. Yasar, N. Aydin, D. Balvan, O. Sener, N. Yuksel, S. Mert, A. Polat, O. Yumuk, F. Kanat, O. Gumus, M. Turhal, N. S. |
container_volume |
15 |
class |
610 ASE |
format_se |
Elektronische Aufsätze |
author-letter |
Korkmaz, T. |
doi_str_mv |
10.1007/s12094-012-0960-6 |
dewey-full |
610 |
author2-role |
verfasserin |
title_sort |
comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis |
title_auth |
Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis |
abstract |
Purpose Small cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment. Methods We retrospectively assessed data of 120 SCLC patients who failed first-line treatment and received second-line treatment at three medical oncology centers. Results Median age of group was 58. 82 % had an ECOG PS of 0–1 at the time of relapse. 39 % were at limited stage (LS) at the time of diagnosis. Patients who progressed more than 3 months after first-line therapy were categorized as having platinum-sensitive disease (PSD) (64 %). The number of patients who received platin-based combination treatment was 33 (27 %). The median OS time starting from the initiation of second-line treatment was 7 months. Multivariate analysis identified PS (p = 0.006), extent of disease at diagnosis (0.014) and PSD (0.001) as the independent prognostic factors for survival. Subgroup analyses of the patients with PSD indicated platin rechallenge yields higher progression-free survival, overall survival and overall response rate. Conclusion Patients with good ECOG PS,who have PSD or initially presenting with LS, have a good prognosis and in patients with PSD, platinum-based therapy would be more appropriate. |
abstractGer |
Purpose Small cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment. Methods We retrospectively assessed data of 120 SCLC patients who failed first-line treatment and received second-line treatment at three medical oncology centers. Results Median age of group was 58. 82 % had an ECOG PS of 0–1 at the time of relapse. 39 % were at limited stage (LS) at the time of diagnosis. Patients who progressed more than 3 months after first-line therapy were categorized as having platinum-sensitive disease (PSD) (64 %). The number of patients who received platin-based combination treatment was 33 (27 %). The median OS time starting from the initiation of second-line treatment was 7 months. Multivariate analysis identified PS (p = 0.006), extent of disease at diagnosis (0.014) and PSD (0.001) as the independent prognostic factors for survival. Subgroup analyses of the patients with PSD indicated platin rechallenge yields higher progression-free survival, overall survival and overall response rate. Conclusion Patients with good ECOG PS,who have PSD or initially presenting with LS, have a good prognosis and in patients with PSD, platinum-based therapy would be more appropriate. |
abstract_unstemmed |
Purpose Small cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment. Methods We retrospectively assessed data of 120 SCLC patients who failed first-line treatment and received second-line treatment at three medical oncology centers. Results Median age of group was 58. 82 % had an ECOG PS of 0–1 at the time of relapse. 39 % were at limited stage (LS) at the time of diagnosis. Patients who progressed more than 3 months after first-line therapy were categorized as having platinum-sensitive disease (PSD) (64 %). The number of patients who received platin-based combination treatment was 33 (27 %). The median OS time starting from the initiation of second-line treatment was 7 months. Multivariate analysis identified PS (p = 0.006), extent of disease at diagnosis (0.014) and PSD (0.001) as the independent prognostic factors for survival. Subgroup analyses of the patients with PSD indicated platin rechallenge yields higher progression-free survival, overall survival and overall response rate. Conclusion Patients with good ECOG PS,who have PSD or initially presenting with LS, have a good prognosis and in patients with PSD, platinum-based therapy would be more appropriate. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 |
container_issue |
7 |
title_short |
Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis |
url |
https://dx.doi.org/10.1007/s12094-012-0960-6 |
remote_bool |
true |
author2 |
Seber, S. Kefeli, U. Sari, E. Canhoroz, M. Oven, B. Yildirim, E. Yasar, N. Aydin, D. Balvan, O. Sener, N. Yuksel, S. Mert, A. Polat, O. Yumuk, F. Kanat, O. Gumus, M. Turhal, N. S. |
author2Str |
Seber, S. Kefeli, U. Sari, E. Canhoroz, M. Oven, B. Yildirim, E. Yasar, N. Aydin, D. Balvan, O. Sener, N. Yuksel, S. Mert, A. Polat, O. Yumuk, F. Kanat, O. Gumus, M. Turhal, N. S. |
ppnlink |
385985452 |
mediatype_str_mv |
c |
isOA_txt |
false |
hochschulschrift_bool |
false |
doi_str |
10.1007/s12094-012-0960-6 |
up_date |
2024-07-04T00:12:13.032Z |
_version_ |
1803605175733059584 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR02426041X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519164619.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201006s2012 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s12094-012-0960-6</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR02426041X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12094-012-0960-6-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Korkmaz, T.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2012</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose Small cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment. Methods We retrospectively assessed data of 120 SCLC patients who failed first-line treatment and received second-line treatment at three medical oncology centers. Results Median age of group was 58. 82 % had an ECOG PS of 0–1 at the time of relapse. 39 % were at limited stage (LS) at the time of diagnosis. Patients who progressed more than 3 months after first-line therapy were categorized as having platinum-sensitive disease (PSD) (64 %). The number of patients who received platin-based combination treatment was 33 (27 %). The median OS time starting from the initiation of second-line treatment was 7 months. Multivariate analysis identified PS (p = 0.006), extent of disease at diagnosis (0.014) and PSD (0.001) as the independent prognostic factors for survival. Subgroup analyses of the patients with PSD indicated platin rechallenge yields higher progression-free survival, overall survival and overall response rate. Conclusion Patients with good ECOG PS,who have PSD or initially presenting with LS, have a good prognosis and in patients with PSD, platinum-based therapy would be more appropriate.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Platinum sensitive disease</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Platinum refracter disease</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Second-line chemotherapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Small cell lung cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Seber, S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kefeli, U.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sari, E.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Canhoroz, M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Oven, B.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yildirim, E.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yasar, N.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Aydin, D.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Balvan, O.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sener, N.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yuksel, S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mert, A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Polat, O.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yumuk, F.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kanat, O.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gumus, M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Turhal, N. S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Revista de oncología</subfield><subfield code="d">Barcelona : Doyma, 2000</subfield><subfield code="g">15(2012), 7 vom: 10. Nov., Seite 535-540</subfield><subfield code="w">(DE-627)385985452</subfield><subfield code="w">(DE-600)2143451-7</subfield><subfield code="x">1578-195X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:2012</subfield><subfield code="g">number:7</subfield><subfield code="g">day:10</subfield><subfield code="g">month:11</subfield><subfield code="g">pages:535-540</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s12094-012-0960-6</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">2012</subfield><subfield code="e">7</subfield><subfield code="b">10</subfield><subfield code="c">11</subfield><subfield code="h">535-540</subfield></datafield></record></collection>
|
score |
7.3974905 |